Navigation Links
Pharmos Announces Results of Phase 2b Irritable Bowel Syndrome Study
Date:9/14/2009

ISELIN, N.J., Sept. 14 /PRNewswire-FirstCall/ -- Pharmos Corporation (Pink Sheets: PARS) announced today the results of its Phase 2b Dextofisopam clinical trial to evaluate safety and efficacy of the compound in irritable bowel syndrome.

Although the primary efficacy variable (% of weeks responding for adequate overall relief of IBS symptoms) did not reach statistical significance, the percentage responding for the Dextofisopam 200 mg group was higher than that observed for the Phase 2a trial. However, the placebo response rate was higher than expected compared to the Phase 2a placebo response.

This result was similarly demonstrated across all other secondary efficacy variables associated with the adequate overall relief question. In all cases except at Month 1, the response rates for the Dextofisopam 200 mg group were essentially the same as or in most cases better than the response rates observed for the Phase 2a trial.

Secondary response variables of adequate relief of abdominal pain and discomfort and overall IBS symptoms ratings showed statistical significance and trends favoring the Dextofisopam 200 mg group compared to placebo.

Further secondary analysis, as well as sub group analysis, is ongoing and will be reported when available.

The Phase 2b double-blind, randomized, placebo-controlled study evaluated the clinical safety, tolerability and efficacy of multiple doses of Dextofisopam. Female outpatients with diarrhea predominant and alternating diarrhea and constipation IBS (according to Rome III Criteria for IBS) were randomized into each of four treatment groups: 100mg, 200mg, and 300mg BID dextofisopam or placebo. A total of 324 patients were enrolled using approximately 70 US centers. The patients participated for up to 19 weeks, including a screening period, a 12-week treatment period, and a 28-day post treatment
'/>"/>

SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Pharmos Restructures Operations in Israel
2. Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
3. Pharmos Corporation Reports 2008 Third Quarter Results
4. Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
5. Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be Achieved
6. Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination
7. Pharmos Completes Private Placement - Raises $1.8 Million
8. Pharmos Corporation Reports 2009 First Quarter Results
9. Pharmos Corporation Reports 2009 Second Quarter Results
10. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
11. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 “After my mom’s ... then had a stroke and loss the use of his left ... to design a way to help people like them enjoy eating ... created a prototype for the PATRICIA CAROL HALL PLATE (P C ... PLATE) offers a more ergonomic way to eat for individuals who ...
(Date:7/12/2014)... York, New York (PRWEB) July 12, 2014 ... continue to move forward in U.S. courts, Bernstein Liebhard ... ties elevated metal ion levels to the failure of ... July 2nd issue of The Journal of Bone & ... had received unilateral Articular Surface Replacement prostheses at least ...
(Date:7/12/2014)... 12, 2014 For those who are unfamiliar ... readily absorb the nutrients in food. The enzymes literally break ... small enough to be absorbed by human bodies. According Dr. ... of enzymes in regular food is the cause of many ... was started by Michelle DelPresto, a mother of 3 who ...
(Date:7/12/2014)... 12, 2014 “Critical Care Therapeutics ... and Late-Stage Four-Factor PCCs and Recombinant Products to ... critical care market in the US, UK, France, ... provides an estimation of market size for 2013, ... critical care indications that are being treated using ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 As reported in ... Institute of Standards and Technology), the June 25th, 2014 Supreme ... electronic discovery world. It was also met with ... depending on whether it was seen from an individual privacy ... much is fact, there is now precedent which will require ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5
... you could not find the price for anything at the ... check-out clerk offered to mail you a bill, but could ... Although that sounds ridiculous, that is exactly how our nation,s ... care reform debate charges forward, the unsustainable rise in health ...
... involved with the chemopreventative effect of aspirin on colorectal adenomas, ... the Journal of the National Cancer Institute . ... polyps, but it,s not clear how it works. One hypothesis ... as C-reactive protein and others, that are markers of inflammation. ...
... might yield insights into diseases like Parkinson,s, experts say , ... genetic mutation seem to be "smarter," in the sense of ... make correct decisions quickly, a new German study suggests. , ... the prefrontal cortex of the brain, activity that is probably ...
... Oct. 12 /PRNewswire-FirstCall/ - HTDS www.htdsmedical.com (HTDS) ... Chem www.slavicabiochem.com is providing an audio recording ... Filing service. The audio recording a wav file can ... transcript and the audio recording covers scientific topics and ...
... Iowa Committee for Value in Healthcare today issued a ... health care that Congress and the Obama administration should ... The committee found that Iowa, nationally recognized for high-value ... reform. Health care providers, purchasers, payers, patient advocates and ...
... Mourning, Kidney Care Partners Call Attention to Extended Medicare ... Access to Quality Care , WASHINGTON, Oct. 12 ... advocates, dialysis professionals, care providers and manufacturers working together ... disease and kidney failure - today applauded the Congressional ...
Cached Medicine News:Health News:Regence Video Asks 'What if Everything Worked Like Health Care?' 2Health News:Regence Video Asks 'What if Everything Worked Like Health Care?' 3Health News:Gene Mutation May Speed Learning 2Health News:Slavica Bio Chem (HTDS) Subsidiary Medical Team Message 2Health News:Slavica Bio Chem (HTDS) Subsidiary Medical Team Message 3Health News:Slavica Bio Chem (HTDS) Subsidiary Medical Team Message 4Health News:Iowa Committee Makes Recommendations to Increase Value in Health Care 2Health News:Iowa Committee Makes Recommendations to Increase Value in Health Care 3Health News:Iowa Committee Makes Recommendations to Increase Value in Health Care 4Health News:Iowa Committee Makes Recommendations to Increase Value in Health Care 5Health News:Kidney Care Community Commends Congressional Black Caucus for Naming Expansion of Medicare Provisions for Kidney Failure Patients as Top Priority 2Health News:Kidney Care Community Commends Congressional Black Caucus for Naming Expansion of Medicare Provisions for Kidney Failure Patients as Top Priority 3
(Date:7/11/2014)... According to a new market ... (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - Global ... the global endoscopy devices market was valued at USD ... at a CAGR of 6.8% from 2013 to 2019, ... in 2019. Browse the full Endoscopy Devices Market ...
(Date:7/11/2014)... Neurelis, Inc. ("Neurelis") today announced an agreement ... held by Biotie to purchase Neurelis, clearing the way ... diazepam) for pediatric and adult epilepsy patients who experience ... Biotie has advanced the development program for NRL-1 and ... work required for NDA submission to the FDA.  Given ...
(Date:7/10/2014)... 2014  Breg, Inc., a premier provider of ... FreeRunner™ knee brace with new innovations to help ... return to active lifestyles.  FreeRunner,s patent-pending design acts ... support when patients need it most, and the ... Patellofemoral issues are the most common cause ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... MADISON, Wis., Aug. 8, 2011 Symphony Corporation, ... the acquisition of JGI, a New Jersey-based Human ... significant presence in the healthcare industry nationally.  Symphony,s ... its offerings to provide the highest level of ...
... DIEGO, Aug. 8, 2011 HUYA Bioscience International, a ... strategic partnership with the Shanghai Jiao Tong University School ... assist King,s Lab in accelerating the development of their ... provides HUYA with access to and first review of ...
Cached Medicine Technology:Symphony Corporation Acquires JGI to Provide End-to-End Services for Healthcare IT 2HUYA Bioscience International and Shanghai Jiao Tong University King's Lab Form Alliance 2HUYA Bioscience International and Shanghai Jiao Tong University King's Lab Form Alliance 3
Diamond Point Bone Probe with Ortho-Grip® silicone rubber palm style handles and,stainless steel impactor caps....
CapSureSP Novus 5594 is a J-shaped, endocardial, tined pacing lead. provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but wi...
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Medicine Products: